gimli
AJANTPHARM stock analysis context
AJANTA PHARMA Stock Context for AI Screening
AJANTA PHARMA LIMITED is a mid-cap stock in Healthcare. This page summarizes key screening signals for AJANTA PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about AJANTPHARMPrice
₹3,107.50
1M return
+11.81%
3M return
+5.72%
Market cap
₹38,823.75 cr
PE
38.02
ROE
+27.76%
RSI
56.25
Turnover
₹12.49 cr
Why it can matter in screens
- Momentum: AJANTPHARM is above 50DMA, above 200DMA; RSI is 56.25.
- Returns: 1M +11.81%, 3M +5.72%, 6M +25.02%.
- Liquidity: latest turnover is ₹12.49 cr.
- Valuation: PE 38.02, PB 8.58, ROE +27.76%, ROCE +35.62%.
- Growth: 3Y sales CAGR +11.78%, 3Y profit CAGR +8.90%.
Try these prompts
- Analyze AJANTA PHARMA with valuation, momentum and industry peers
- Compare AJANTPHARM with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare AJANTPHARM with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.